Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia (Q24805262)

2

0 references

Judith E Karp

3

0 references

Jeffrey E Lancet

4

0 references

David Atkins

5

0 references

Yixin Wang

https://scigraph.springernature.com/pub.10.1186/1471-2407-4-56

6

0 references

language of work or name

English

0 references

publication date

25 August 2004

0 references

published in

BMC Cancer

0 references

volume

4

0 references

issue

1

0 references

page(s)

56

0 references

exact match

0 references

cites work

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Genetic response to farnesyltransferase inhibitors: proapoptotic targets of RhoB.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Farnesyl transferase inhibitors as anticancer agents

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Farnesyltransferase inhibitors: promises and realities

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

The phosphoinositide 3-OH kinase/AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

28 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-56

Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-56

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-56

Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-56

Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-4-56

Comparison of potential markers of farnesyltransferase inhibition

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=516036